| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/01/2002 | WO2001095916A3 Anticholestatic medicament containing luteolin-7-o-glucuronide |
| 08/01/2002 | WO2001091587A3 Oil compositions comprising short, medium and long chain triglycerides and use thereof in reducing weight gain |
| 08/01/2002 | WO2001089319A3 Tryptophan source from plants and uses therefor |
| 08/01/2002 | WO2001085148A3 Packaging regimen of pseudoephedrine hydrochloride and fexofenadine hydrocloride |
| 08/01/2002 | WO2001085106A3 Cosmetic agents containing 2-furanone derivatives |
| 08/01/2002 | WO2001082914A3 Topical anesthetic/opioid formulations and uses thereof |
| 08/01/2002 | WO2001081325A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 08/01/2002 | WO2001078697A3 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| 08/01/2002 | WO2001078654A3 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 08/01/2002 | WO2001078530A3 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
| 08/01/2002 | WO2001076606A3 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like |
| 08/01/2002 | WO2001072335A3 Methods for effecting neuroprotection using a potassium channel modulator |
| 08/01/2002 | WO2001070955A3 Identification of essential genes in prokaryotes |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001070204A3 Highly selective inhibitors of the urokinase plasminogen activator |
| 08/01/2002 | WO2001064202A3 Tramadol for the treatment of functional gastrointestinal disorders |
| 08/01/2002 | WO2001062290A3 Methods and compositions for improving sleep |
| 08/01/2002 | WO2001041754A9 Inhibitors of collagen-induced platelet aggregation |
| 08/01/2002 | WO2001028494A9 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 08/01/2002 | WO2001022970A9 Therapy with 2-5a and interferon |
| 08/01/2002 | WO2001012206A3 Soy-glycine extracts and aromatase inhibitors for positively influencing collagen |
| 08/01/2002 | US20020104108 Expression vector coding polypeptides for use in the treatment of alzheimer's dieases and tumors |
| 08/01/2002 | US20020103398 Double bond acts as a rigidifying element, for unexpected potency and selectivity for inhibition of inducible nitric oxide synthase over the constitutive isoforms |
| 08/01/2002 | US20020103392 Corticoid-17,21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters, processes for their preparation and pharmaceuticals containing these compounds |
| 08/01/2002 | US20020103389 Klainetins and their derivatives, method for their preparation and use thereof |
| 08/01/2002 | US20020103386 Physalis angulata extracts, particularly ergostane-type steroidal derivatives, physalins, useful as antiprotozoa agents and as immunomodulators |
| 08/01/2002 | US20020103384 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| 08/01/2002 | US20020103383 Selective 5-HT6 receptor ligands |
| 08/01/2002 | US20020103382 Serotonin (5-HT) subtype 6 receptor (5-HT6); 3-(2-aminoethyl)indole derivatives; drug screening |
| 08/01/2002 | US20020103380 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction |
| 08/01/2002 | US20020103379 Making 2,2-difluoro-2-(2-pyridyl)-ethan-1-ol, by coupling 2-bromopyridine with ethyl 2-bromo-2,2-difluoroacetate, using metallic copper and solvent; chemical intermediates |
| 08/01/2002 | US20020103377 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms |
| 08/01/2002 | US20020103376 Dithiepino[6,5-b]pyridines, and related compositions and methods |
| 08/01/2002 | US20020103371 Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives |
| 08/01/2002 | US20020103335 Peptide derivatives |
| 08/01/2002 | US20020103262 Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus |
| 08/01/2002 | US20020103261 Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
| 08/01/2002 | US20020103260 Combinations of formoterol and fluticasone proppionate for asthma |
| 08/01/2002 | US20020103258 Administering to the cow at least one of an ester of methionine, an ester of methionine amide, and an ester of hydroxy analogue of methionine, or salt of atleast one ester to increase milk production |
| 08/01/2002 | US20020103257 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 08/01/2002 | US20020103255 Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| 08/01/2002 | US20020103254 Paclitaxel formulation |
| 08/01/2002 | US20020103253 Administering aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases |
| 08/01/2002 | US20020103252 Statin-carboxyalkylether combinations |
| 08/01/2002 | US20020103251 Cholesterol-lowering therapy |
| 08/01/2002 | US20020103250 Method of treatment or prophylaxis |
| 08/01/2002 | US20020103249 Combination of a serotonin reuptake inhibitor and irindalone |
| 08/01/2002 | US20020103248 Indole derivatives which are agonists of the progesterone receptor and useful for treatment of carcinoma and adenocarcinomas of uterine leiomyomata, endometriosis or polycystic ovary syndorme in a mammal |
| 08/01/2002 | US20020103247 Indole and dihydroindole derivatives |
| 08/01/2002 | US20020103245 1-aryl or heteroaryl substituted 5-amino-4 carbonylpyrazole derivatives; antiinflammatory agents |
| 08/01/2002 | US20020103244 Antifatigue composition |
| 08/01/2002 | US20020103242 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/01/2002 | US20020103241 Such as N-benzooxazol-2-yl-3-cyclopentyl-2-(4-methanesulfonyl -phenyl)-propionamide for increasing insulin secretion in the treatment of type II diabetes |
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103237 For decreasing amphetamine-induced hyperactivity |
| 08/01/2002 | US20020103236 Use of tiagabine for treatment of diabetic neuropathy and migraine |
| 08/01/2002 | US20020103235 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 08/01/2002 | US20020103234 Heterocycl-containing carboxylic acid derivative and drug containing the same |
| 08/01/2002 | US20020103232 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| 08/01/2002 | US20020103231 Such as 4-chloro-N-(4-(6-chloro-3a-hydroxy-8,8a-dihydro-3aH-indeno(1,2-d)thiazol-2 -yl)-phenyl)benzene-sulfonamide; for the prophylaxis or treatment of obesity |
| 08/01/2002 | US20020103230 Heterocyclic compounds |
| 08/01/2002 | US20020103229 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 08/01/2002 | US20020103228 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 08/01/2002 | US20020103227 Nitric oxide synthase inhibitors such as 6(4'-(4-phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl)-pyridin-2-ylamine for treatment and prevention of central nervous system disorders |
| 08/01/2002 | US20020103225 Comprises solid amorphous dispersion of compounds such as (2R,4S)4-((3,5-dichloro-benzyl)-methoxycarbonyl-amino)-6,7-dimethoxy-2 -methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester for elevating plasma lipid levels |
| 08/01/2002 | US20020103223 Soy formulations and their use for promoting health |
| 08/01/2002 | US20020103222 Oxygenating storage media by adding oxygen, carbon dioxide, and pure emulsified perfluorocarbons; for transplant organs (especially corneas) |
| 08/01/2002 | US20020103221 Such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide or prodrug thereof; for improving functional health of elderly/isolated |
| 08/01/2002 | US20020103220 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4- dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors |
| 08/01/2002 | US20020103219 Mucoadhesive (linear or crosslinked polyacrylic acid, hydroxyalkylcellulose, or dextran sulphate) for drug delivery of antiulcer/antiinflammatory agents |
| 08/01/2002 | US20020103218 Anhydrovinblastine for the treatment of cancer |
| 08/01/2002 | US20020103217 Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids |
| 08/01/2002 | US20020103216 6-substituted pyrimidine 3-oxides for promoting pigmentation of the skin/hair |
| 08/01/2002 | US20020103214 Novel heteroaryl derivatives and their use as medicaments |
| 08/01/2002 | US20020103213 Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis |
| 08/01/2002 | US20020103212 Pharmaceutical compositions containing anti-fas antibody |
| 08/01/2002 | US20020103211 For treatment of chronic inflammatory disease, chronic intestinalinflammation, arthritis, psoriasis, asthma, autoimmune disorders |
| 08/01/2002 | US20020103210 Nitrogen-containing heterocyclic compounds, their production and use |
| 08/01/2002 | US20020103209 Serotonergic modulators; for treatment of disorders of the central nervous system including psychotic disorders, hypertension and vascular disorders, migraine |
| 08/01/2002 | US20020103206 Use of the selective 5-HT2C receptor agonists 1-(6-chloro-5-(trifluoromethyl)-2-pyridinyl)-piperazine and (S)-(+)-3-((2,3-dihydro-5-methoxy-1H-inden-4-yl)oxy-pyrrolidine |
| 08/01/2002 | US20020103205 Muscarinic antagonists |
| 08/01/2002 | US20020103203 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis |
| 08/01/2002 | US20020103202 Heteroaryl-phenyl substituted factor Xa inhibitors |
| 08/01/2002 | US20020103200 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
| 08/01/2002 | US20020103199 Fused heteroaromatic glucokinase activators |
| 08/01/2002 | US20020103198 Acylamino cyclopropane derivatives |
| 08/01/2002 | US20020103197 For use in protecting human and animal hair and skin against damaging action of UV radiation |
| 08/01/2002 | US20020103196 Stabilizing pharmaceutical composition by contacting with polymeric material containing an antioxidant; eye drops |
| 08/01/2002 | US20020103191 Antitumor dibenzofluorene derivatives |
| 08/01/2002 | US20020103190 Azo amino acids derivatives |
| 08/01/2002 | US20020103187 Compositions and methods for treating superficial fungal infections |
| 08/01/2002 | US20020103186 Use against multiply resistant gram positive pathogens; have a diazine moiety attached to the phenyloxazolidinone which is further substituted by heterocyclic, aryl, substituted aryl, heteroaroamatic ring |
| 08/01/2002 | US20020103184 Cyclic malonamides as inhibitors of a beta protein production |
| 08/01/2002 | US20020103183 Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example |
| 08/01/2002 | US20020103182 Improving elasticity or reducing wrinkles of a skin, for example; advanced glycosylation endproducts" or AGEs |
| 08/01/2002 | US20020103181 Specifically betalactam antibiotic, and mixture of sodium alginate and/or xanthan gum, and optionally probenecid as either immediate release or controlled release, in specified weights; once or twice daily dosage |
| 08/01/2002 | US20020103179 Soluble contraceptive liquid formulation |
| 08/01/2002 | US20020103178 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 08/01/2002 | US20020103177 E.g. 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one; controlling male fertility; stereospecific synthesis starting from adrenosterone, and introducing the 7alpha substituent prior to an 11-substituent |
| 08/01/2002 | US20020103176 Male contraceptive formulation comprising norethisterone |